ARTICLE | Emerging Company Profile
Vicinitas: stabilizing proteins with small molecules
a16z, Deerfield co-lead $65M series A for UC Berkeley spinout’s small molecule deubiquitination platform
July 28, 2022 11:36 PM UTC
Fueled by a $65 million series A round led by a16z and Deerfield, Vicinitas launched Thursday to build small molecule-based deubiquitinase-targeting chimeras designed to stabilize otherwise “undruggable” proteins whose degradation is associated with disease.
Vicinitas Therapeutics Inc., a University of California Berkeley spinout co-founded by Dan Nomura and Novartis Institutes for BioMedical Research (NIBR), is one of many companies developing TACs, or therapeutic targeting chimeras...